Big Pharmas R&D Strategy in Oncology & Lung Cancer and Melanoma

Table of Contents

1 Executive Summary

2 Methodologies

3 Table of Contents

• 3.1 List of Tables
• 3.2 List of Boxes

4 Big Pharma' s R&D Position and Strategy in Oncology: A Summary

• 4.1 Bristol-Myers Squibb
• 4.2 GlaxoSmithKline
• 4.3 Hoffmann-La Roche
• 4.4 Novartis
• 4.5 Sanofi-Aventis

5 Last Five Years of Deals and Alliances in Oncology

• 5.1 Bristol Myers Squibb
  • 5.1.1 Discovery and Lead Molecule Improvements
  • 5.1.2 Adding Image Analysis to Support Clinical Trials and Early Diagnosis
  • 5.1.3 Bladder Cancer and Melanoma Registration Filings are Emminent
  • 5.1.4 The Human Kinome and Cell Cycle Inhibitors
  • 5.1.5 Strategic Priorities in Pipeline Development Leads to Divestments
  • 5.1.6 Erbitux Expansion is Set to Challenge Avastin
• 5.2 GlaxoSmithKline
  • 5.2.1 The Biopharmaceutical Strategy at GSK
  • 5.2.2 Out Goes Classes of Small Molecule Inhibitors
  • 5.2.3 Marketing and Manufacturing Collaborations
  • 5.2.4 Patient Selectionfo r GSK' s Targeted Cancer Therapies
  • 5.2.5 GSK Taping Into Knowledge Databases
  • 5.2.6 Increasing the Oral Bioavailability Cytotoxic Oncology Drugs
  • 5.2.7 Oxford University Helps GSK in India
  • 5.2.8 GSK is Set to Improve Medical Imaging
• 5.3 Hoffmann-La Roche
  • 5.3.1 Roche Builds Center of Excellence for RNAi Therapeutics Discovery
  • 5.3.2 A New Delivery Route for Avastin?
  • 5.3.3 Improving Antibody Drugs
  • 5.3.4 Roche Strengthens Presence in Genomics Research Market
  • 5.3.5 Target Validation
  • 5.3.6 Drug Discovery Collaborations
  • 5.3.7 Marketing
  • 5.3.8 Outlicensing
  • 5.3.9 Size Doesn' t Matter: Genentech' s Goal of Aggressively Pursuing Novel and Innovative Therapies
• 5.4 Novartis
  • 5.4.1 Novartis Acquisition of Chiron: A Major Biopharmaceutical Investment
  • 5.4.2 Protein Kinase Inhibitors
  • 5.4.3 Next Generation Oral Topoisomerase Inhibitor and Telomerase Promotors
  • 5.4.4 Novartis Sells of World-Wide Rights
  • 5.4.5 Biomarker and Proteomics Research
• 5.5 Sanofi-Aventis
  • 5.5.1 Target Screening and Validation
  • 5.5.2 Biologicals
  • 5.5.3 A Short Cut to Success?
  • 5.5.4 Aventis Divests Interest
  • 5.5.5 Recombine My Molecule

6 Competitive R&D Comparison on Oncology Drug Target Level

• 6.1 Target Overview
• 6.2 Head to Head Target Comparison by Molecular Function and Cancer Type
  • 6.2.1 Transmembrane Receptor Protein Tyrosine Kinase Activity Targets
  • 6.2.2 Receptor Activity Targets
  • 6.2.3 G-protein Coupled Receptor Activity Targets
  • 6.2.4 Protein Serine/Threonine Kinase Activity Targets
  • 6.2.5 Transcription Factor Activity Targets
  • 6.2.6 Transmembrane Receptor Activity Targets
  • 6.2.7 Catalytic Activity Targets
  • 6.2.8 Cytokine Activity Targets
  • 6.2.9 Protein-Tyrosine Kinase Activity Targets
  • 6.2.10 Kinase Activity Targets
  • 6.2.11 DNA Topoisomerase Activity Targets
  • 6.2.12 Growth Factor Activity Targets
  • 6.2.13 Ligase Activity Targets
  • 6.2.14 Motor Activity Targets
  • 6.2.15 Structural Constituent of Cytoskeleton Targets
  • 6.2.16 Transporter Activity Targets
  • 6.2.17 Targets According to Miscellaneous Molecular Function Groups
  • 6.2.18 Unclassified or Unknown Molecular Function of Targets
• 6.3 Drug Targets by Target Localization and Compound Type
• 6.4 Targets, Drugs and Cancer Indications Linked to Signaling Pathways
  • 6.4.1 Alpha6 Beta4 Integrin Signaling Pathway
  • 6.4.2 Androgen Receptor Signaling Pathway
  • 6.4.3 B Cell Receptor Signaling Pathway
  • 6.4.4 EGFR1 Signaling Pathway
  • 6.4.5 Hedgehog Signaling Pathway
  • 6.4.6 ID Signaling Pathway
  • 6.4.7 IL-1 Signaling Pathway
  • 6.4.8 IL-2 Signaling Pathway
  • 6.4.9 IL-3 Signaling Pathway
  • 6.4.10 IL-4 Signaling Pathway
  • 6.4.11 IL-5 Signaling Pathway
  • 6.4.12 IL-6 Signaling Pathway
  • 6.4.13 IL-9 Signaling Pathway
  • 6.4.14 Kit Receptor Signaling Pathway
  • 6.4.15 Notch Signaling Pathway
  • 6.4.16 T Cell Receptor Signaling Pathway
  • 6.4.17 TGF-beta Receptor Signaling Pathway
  • 6.4.18 TNF-alpha Signaling Pathway
  • 6.4.19 Wnt Signaling Pathway

7 Drug Compound Type Analysis

• 7.1 Deployment of Biological Based Compounds by Cancer Indications
• 7.2 Deployment of Chemical Based Compounds by Cancer Indications
• 7.3 Deployment of Natural Product Compounds by Cancer Indications

8 Drug Development in Oncology by Major Targeted Therapy Areas

• 8.1 Angiogenesis
• 8.2 Antibodies
• 8.3 Apoptosis
• 8.4 Protein Kinase Inhibitors
• 8.5 Vaccines

9 Cancer Indication Focus Analysis

• 9.1 Preclinical Stage Pipeline
• 9.2 Phase I Clinical Stage Pipeline
• 9.3 Phase II Clinical Stage Pipeline
• 9.4 Phase III Clinical Stage Pipeline
• 9.5 Drugs Soon to be on the Market
• 9.6 Approved Drugs

10 Lung cancer: An Introduction

• 10.1 Current Treatment Strategies
• 10.2 Disease Definition
• 10.3 Etiology & Pathophysiology
• 10.4 Prognosis
• 10.5 Epidemiology

11 Progress in Current Lung Cancer Treatment Strategies

• 11.1 Improvements Adding microtubule Inhibitor
• 11.2 Improvement of Disease Related Symptoms in Elderly Patients
• 11.3 Toxicity Profile Favored
• 11.4 A New Formula
• 11.5 Monotherapy?
• 11.6 Failed to Demonstrate a Survival Advantage
• 11.7 Reduction in Mortality Risk

12 Key Drug Strategies in Lung Cancer

• 12.1 Apoptosis
• 12.2 Antiangiogenesis and Antivascular Agents
  • 12.2.1 EGFR and VEGFR as target
  • 12.2.2 Immunotherapy

13 Competitive Landscape in Lung Cancer Drug Development: The Late Stage Pipeline

• 13.1 Grade 4 Adverse Events
• 13.2 No New Remarks
• 13.3 No Significant Effect on Overall Survival
• 13.4 Bristol Myers Squibb Entered into an Agreement
• 13.5 Many Uncertainties Remain
• 13.6 Development Terminated
• 13.7 Continuing Enrollment
• 13.8 Apoptotic Inducer
• 13.9 Fully-Human Monoclonal Antibody
• 13.10 Eagerly Awaiting Data
• 13.11 Mutations and Response
• 13.12 Statistically and Clinically Significant Survival Advantage
• 13.13 Anti-Idiotypic Monoclonal Antibody
• 13.14 Shift in the Development Focus
• 13.15 Sensitizer
• 13.16 Treatment in Earlier-Stage Cancer Could be More Effective
• 13.17 Discontinued Radiosensitizer
• 13.18 Improvement in Chemoradiotherapy
• 13.19 Progress on HDAC Inhibitor
• 13.20 Progress Analysis Carboxyamidotriazole
• 13.21
• 13.22 Chemotherapy naïve subjects

14 Etiology and Pathophysiology of Melanoma

15 Current Melanoma Treatment Strategies

• 15.1 An Overview
• 15.2 Cytotoxic Drugs
  • 15.2.1 Dacarbazine
  • 15.2.2 Cisplatin
  • 15.2.3 Carboplatin
  • 15.2.4 Carmustine
  • 15.2.5 Melphalan
  • 15.2.6 Paclitaxel
  • 15.2.7 Tamoxifen
  • 15.2.8 Temozolomide
  • 15.2.9 Vinblastine/Vinorelbine
• 15.3 Biological treatments
  • 15.3.1 Intron A
  • 15.3.2 Virulizin
  • 15.3.3 Melacine
  • 15.3.4 Alfanative (Multiferon)
  • 15.3.5 Proleukin or (Macrolin)
  • 15.3.6 Enhanzyn
  • 15.3.7 M-VAX
• 15.4 Other
  • 15.4.1 Ceplene Maxamine

16 Key Melanoma Therapy Strategies

• 16.1 Immunotherapy
• 16.2 Anti-angiogenesis
• 16.3 Apoptotic Induction
• 16.4 Gene Therapy

17 Current Melanoma Drug Development: Late Stage Pipeline

• 17.1 Immunotherapy
  • 17.1.1 Oncophage
  • 17.1.2 Canvaxin
  • 17.1.3 GMK
  • 17.1.4 MDX-010
  • 17.1.5 OncoVax
  • 17.1.6 ALLOVECTIN-7
  • 17.1.7 Peginterferon alfa-2b
• 17.2 Anti-angiogenesis
  • 17.2.1 Lenalidomide
• 17.3 Apoptotic Inducers
  • 17.3.1 Genasense
• 17.4 Inhibiting Cell Growth
  • 17.4.1 Temozolomide
• 18 Current Melanoma Drug Development: Early Stage Pipeline
• 18.1 Immunotherapy
  • 18.1.1 INGN 241
  • 18.1.2 QS-21
  • 18.1.3 Talabostat
  • 18.1.4 SB 249553
  • 18.1.5 GVAX
  • 18.1.6 GV 1001
  • 18.1.7 Dexosome
  • 18.1.8 Uvidem
  • 18.1.9 NY-ESO-1 ISCOMS
  • 18.1.10 NOVOVAC-M1
  • 18.1.11 Oxxon Vaccine
  • 18.1.12 Therion' s Melanoma Vaccine
  • 18.1.13 ImmunoVex trimelan
  • 18.1.14 OncoVEXGM-CSF
  • 18.1.15 Zadaxin
  • 18.1.16 Alvac-Mage1/Mage3
  • 18.1.17 Iboctadekin
  • 18.1.18 ProMune
  • 18.1.19 BAY 504798
  • 18.1.20 EMD 273063
• 18.2 Antiangiogenesis
  • 18.2.1 Sorafenib
  • 18.2.2 Vitaxin
  • 18.2.3 Avastin
  • 18.2.4 PI 88
• 18.3 Apoptotic Inducers
  • 18.3.1 Didemnin B
  • 18.3.2 KOS 953
• 18.4 Small Molecules Inhibiting Cell Growth
  • 18.4.1 Pivanex
  • 18.4.2 Karenitecin
  • 18.4.3 Lomeguatrib
  • 18.4.4 PD 0325901
  • 18.4.5 SB 715992
  • 18.4.6 INO 1001
  • 18.4.7 CP 4055
• 18.5 Other Biological Drugs
  • 18.5.1 AP 12009
  • 18.5.2 Ecromeximab
  • 18.5.3 ILX 651
  • 18.5.4 Kahalalide F
  • 18.5.5 ABX MA1
  • 18.5.6 MJV 101
  • 18.5.7 A Russian Melanoma Vaccine
  • 18.5.8 Elea Vaccine
  • 18.5.9 F 50040

19 Appendix 1. Treatment Guide Lines Lung Cancer*

• 19.1 References

20 Appendix 2: Selected Company Profiles

• 20.1 Abgenix
• 20.2 Aphton
• 20.3 AstraZeneca
• 20.4 Bristol-Myers Squibb
• 20.5 Eli Lilly
• 20.6 Genentech
• 20.7 Genta
• 20.8 GlaxoSmithKline
• 20.9 ImClone
• 20.10 ISIS Pharmaceuticals
• 20.11 Ligand Pharmaceuticals
• 20.12 OSI Pharmaceuticals
• 20.13 Pfizer
• 20.14 Pharmacyclics
• 20.15 Sanofi- Aventis
• 20.16 Telik

21 Appendix 3 Progress profiles on approved drugs

• 21.1 Docetaxel
• 21.2 Vinorelbine
• 21.3 Gemcitabine
• 21.4 Paclitaxel
• 21.5 Pemetrexed
• 21.6 Gefitinib
• 21.7 Erlotinib

22 Appendix 4: Treatment Guide Lines Melanoma

23 Disclaimer

24 Drug Index

25 Company Index

3.1 List of Tables

• Table 1: How to Navigate the Report
• Table 2: Number of Pursued Oncology Drugs Targets by Company
• Table 3: Pursued Oncology Drugs Targets by Molecular Function
• Table 4: Drug Target Expression Profiles in Humans
• Table 5: Identified Targets By Cancer Indications
• Table 6: Head to Head Comparison of Drugs with Transmembrane Receptor Protein Tyrosine Kinase Activity Targets
• Table 7: Head to Head Comparison of Drugs with Receptor Activity Targets
• Table 8: Head to Head Comparison of Drugs with G-protein Coupled Receptor Activity
• Table 9: Head to Head Comparison of Drugs with Protein Serine/Threonine Kinase Activity
• Table 10: Head to Head Comparison of Drugs with Transcription Factor Activity Targets
• Table 11: Head to Head Comparison of Drugs with Transmembrane Receptor Activity Targets
• Table 12: Head to Head Comparison of Drugs with Catalytic Activity Targets
• Table 13: Head to Head Comparison of Drugs with Cytokine Activity Targets
• Table 14: Head to Head Comparison of Drugs with Protein-Tyrosine Kinase Activity Targets
• Table 15: Head to Head Comparison of Drugs with Kinase Activity Targets
• Table 16: Head to Head Comparison of Drugs with DNA Topoisomerase Activity Targets
• Table 17: Head to Head Comparison of Drugs with Growth Factor Activity Targets
• Table 18: Head to Head Comparison of Drugs with Ligase Activity Targets
• Table 19: Head to Head Comparison of Drugs with Motor Activity Targets
• Table 20: Head to Head Comparison of Drugs with Structural Constituent of Cytoskeleton Targets
• Table 21: Head to Head Comparison of Drugs with Transporter Activity Targets
• Table 22: Head to Head Comparison of Drugs with Targets According to Miscellaneous Molecular Function Groups
• Table 23: Head to Head Comparison of Drugs with Unclassified or Unknown Molecular Function Targets
• Table 24: Drug Target Comparison by Target Localization and Compound Type
• Table 25: Targeting Signaling Pathways: An Overview
• Table 26: Targeted Signaling Pathway Profiles of Big Pharma
• Table 27: Targets, Drugs and Cancer Indications Linked to the Alpha6 Beta4 Integrin Signaling Pathway
• Table 28: Targets, Drugs and Cancer Indications Linked to the Androgen Receptor Signaling Pathway
• Table 29: Targets, Drugs and Cancer Indications Linked to the B Cell Receptor Signaling Pathway
• Table 30: Targets, Drugs and Cancer Indications Linked to the EGFR1 Signaling Pathway
• Table 31: Targets, Drugs and Cancer Indications Linked to the Hedgehog Signaling Pathway
• Table 32: Targets, Drugs and Cancer Indications Linked to the ID Signaling Pathway
• Table 33: Targets, Drugs and Cancer Indications Linked to the IL-1 Signaling Pathway
• Table 34: Targets, Drugs and Cancer Indications Linked to the IL-3 Signaling Pathway
• Table 35: Targets, Drugs and Cancer Indications Linked to the IL-4 Signaling Pathway
• Table 36: Targets, Drugs and Cancer Indications Linked to the IL-5 Signaling Pathway
• Table 37: Targets, Drugs and Cancer Indications Linked to the IL-6 Signaling Pathway
• Table 38: Targets, Drugs and Cancer Indications Linked to the Kit Receptor Signaling Pathway
• Table 39: Targets, Drugs and Cancer Indications Linked to the Notch Signaling Pathway
• Table 40: Targets, Drugs and Cancer Indications Linked to the T Cell Receptor Signaling Pathway
• Table 41: Targets, Drugs and Cancer Indications Linked to the TGF-beta Receptor Signaling Pathway
• Table 42: Targets, Drugs and Cancer Indications Linked to the TNF-alpha Signaling Pathway
• Table 43: Targets, Drugs and Cancer Indications Linked to the Wnt Signaling Pathway
• Table 44: Deployment of Biological Based Compounds by Cancer Indications
• Table 45: Deployment of Chemical Based Compounds by Cancer Indications
• Table 46: Deployment of Natural Product Based Compounds by Cancer Indications
• Table 47: Comparative Presentation of Targeted Therapy Areas in Oncology
• Table 48: The Angiogenesis Pipeline by Cancer Type and Developmental Stage
• Table 49: The Antibody Pipeline by Cancer Type and Developmental Stage
• Table 50: The Apoptosis Pipeline by Cancer Type and Developmental Stage
• Table 51: The Protein Kinase Inhibitor Pipeline by Cancer Type and Developmental Stage
• Table 52: The Cancer Vaccine Pipeline by Cancer Type and Developmental Stage
• Table 53: Summary of Big Pharma' s Preclinical Stage Pipeline
• Table 54: Preclinical Stage Pipeline by Cancer Indications
• Table 55: Summary of Big Pharma' s Phase I Clinical Stage Pipeline
• Table 56: : Phase I Clinical Stage Pipeline by Cancer Indications
• Table 57: Summary of Big Pharma' s Phase II Clinical Stage Pipeline
• Table 58: Phase II Clinical Stage Pipeline by Cancer Indications
• Table 59: Summary of Big Pharma' s Phase III Clinical Stage Pipeline
• Table 60: Phase III Clinical Stage Pipeline by Cancer Indications
• Table 61: Oncology Drugs Soon to be on the Market
• Table 62: Summary of Big Pharma' s Approved Oncology Drugs
• Table 63: Approved Drugs by Cancer Indications
• Table 64: Chemotherapeutic drugs for treatment of NSCLC
• Table 65. Near Term Approved Drugs for the Treatment of NSCLC
• Table 66: Chemotherapy Drugs off Patent
• Table 67 Generalized Illustration, Depicting the Key Elements Involved in the Apoptotic Pathways
• Table 68 VTA agents under development
• Table 69 EGFR or VEGFR inhibitors
• Table 70: FMS-like tyrosine kinases and their Synonyms
• Table 71: Fms-related Tyrosine Kinase Targets in Development
• Table 72: Protein Kinase Targets in Clinical Trials for Lung Cancer
• Table 73 Cancer immunotherapy strategies
• Table 74 Recently presented studies Lapatinib
• Table 75 Recently presented studies ZD-6474
• Table 76 Recently presented studies vinflunine
• Table 77 Recently presented studies Panitumumab
• Table 78 Recently presented studies Genasense
• Table 79 Recently presented studies cetuximab
• Table 80 Recently presented studies bevacizumab
• Table 81 Recently presented studies bexarotene
• Table 82 Recently presented studies Xcytrin
• Table 83: Critical Risk Factors for Development of Melanoma
• Table 84: Definition and Description of Stages of Melanoma
• Table 85: Prognosis of the 4 Stages of Malignant Melanoma
• Table 86: Current Cytotoxic Drugs for the Treatment of Melanoma
• Table 87: Progress Profile Dacarbazine
• Table 88: Progress Profile Cisplatin
• Table 89: Progress Profile Carboplatin
• Table 90: Progress Profile Carmustine
• Table 91: Progress Profile Melphalan
• Table 92: Progress Profile Paclitaxel
• Table 93: Progress Profile Tamoxifen
• Table 94: Progress Profile Temozolomide
• Table 95: Progress Profile Vinblastine/Vinorelbine
• Table 96: Progress Profile Interferon alfa-2b
• Table 97: Development Milestones- Virulizin
• Table 98: Development Milestones - Melacine
• Table 99: Development Milestones - Alfanative
• Table 100: Development Milestones - Proleukin
• Table 101: Deployed Strategies for Blocking Angiogenesis
• Table 102: Phase III Randomized Studies of Melanoma Vaccines.
• Table 103: Tumor antigen based vaccines
• Table 104: In vivo Gene Therapy
• Table 105: Cell Therapy Based Platform in Pipeline as Potential Treatment of Melanoma
• Table 106: Ex vivo gene therapy loading of antigen presenting cells
• Table 107: Overview of Immunostimulants in Development based on Type
• Table 108: Overview of Immuno-Biologicals
• Table 109: Overview of Gene Therapy Drugs for Immunostimulation
• Table 110: MDX-010' s Collaborative History and Landscape
• Table 111: Anti-angiogenisis Drugs under Development
• Table 112: Overview Apoptopic Inducer Drugs
• Table 113: Overview of Small Molecule Drugs
• Table 114:Selected Regulatory Progress of Sorafenib
• Table 115: Selected Regulatory Progress of Didemin B
• Table 116: Overview of Various Biological Drugs in Development for Melanoma

List of Boxes

• Box 1: Quick facts on Docetaxel
• Box 2: Scientific Data on Docetaxel
• Box 3: Quick Facts - Vinorelbine
• Box 4: Scientific Data on Vinorelbine
• Box 5: Quick Facts - Gemcitabine
• Box 6: Scientific Data on gemcitabine
• Box 7: Quick Facts - pemetrexed
• Box 8: Scientific Data on Pemetrexed
• Box 9: Quick Facts - Gefitinib
• Box 10: Scientific Data on Gefitinib
• Box 11: Quick Facts - Erlotinib
• Box 12: Quick Facts - Enhanzyn
• Box 13: Quick Facts - M-VAX
• Box 14: M-VAX - Business & Market Bakground
• Box 15: Mechanisms which Tumor Cells use to Evade an Immune Reaction
• Box 16: Introgen' s INGN 241 Shows Vaccine Properties
• Box 17: Quick Facts - Oncophage
• Box 18: Oncophage - Designation and Status
• Box 19: Quick Facts - Canvaxin
• Box 20: Canvaxin - Designation and Status
• Box 21: CancerVax Milestone payment
• Box 22: Quick Facts - GM2-KLH Vaccine
• Box 23: Progenics Reaquires Rights to Vaccine
• Box 24: Completed Melanoma Phase III trials
• Box 25: Quick Facts - MDX-010
• Box 26: Quick Facts -OncoVax
• Box 27: Quick Facts - ALLOVECTIN-7
• Box 28: Quick Facts - Peginterferon alfa-2b
• Box 29: Introgen' s INGN 241 Shows Anti-angiogenesis Properties
• Box 30: Quick Facts - Lenalidomide
• Box 31: Quick Facts - Oblimersen
• Box 32: Quick Facts - Temozomide
• Box 33: Molecular Pathways Underlying the Activity of Temozolomide' s Anti-Cancer Therapy
• Box 34: Regulatory Progress
• Box 35: Quick Facts - INGN 241
• Box 36: Molecular Pathways Underlying Activity of Introgen' s INGN 241 Anti-Cancer Therapy
• Box 37: Quick Facts - QS-21
• Box 38: Quick Facts - Talabostat
• Box 39: Quick Facts - SB 249553
• Box 40: Quick Facts - GVAX
• Box 41: Agreement Japan Tobacco and Cell Genesys
• Box 42: Predicted launch of GVAX
• Box 43: Quick Facts - GV 1001
• Box 44: Quick Facts - Dexosome
• Box 45: Important Milestones and License Fees
• Box 46: Quick Facts - Uvidem
• Box 47: Agreements Between Sanofi-Aventis and IDM
• Box 48: Quick Facts - NY-ESO-1 ISCOMS
• Box 49: NY-ESO-1 and ISCOMATRIX
• Box 50: Quick Facts - NovoVac-M1
• Box 51: Quick Facts - Oxxon vaccine
• Box 52: Quick Facts - Therion' s Melanoma Vaccine
• Box 53: Quick Facts - ImmunoVEX trimelan
• Box 54: Quick Facts - OncoVEX GM-CSF
• Box 55: Quick Facts - ZADAXIN
• Box 56: Developmental History Thymosin alpha1
• Box 57: Quick Facts - Alvac-Mage1/Mage3
• Box 58: Quick Facts - iboctadekin
• Box 59: Quick Facts - PF-3512676
• Box 60: Quick Facts - BAY-504798
• Box 61: Quick Facts - EMD-273063
• Box 62: Quick Facts - Sorefenib
• Box 63: Quick Facts - Vitaxin
• Box 64: Quick Facts . Bevacizumab
• Box 65: Quick Facts - PI88
• Box 66: Quick Facts - Didemnin B
• Box 67: Quick Facts - KOS 953
• Box 68: Quick Facts - Pivanex
• Box 69: Quick Facts - Karenitecin
• Box 70: Company Statement
• Box 71: Quick Facts - Lomeguatrib
• Box 72: Quick Facts - PD 0325901
• Box 73: Quick Facts - SB 715992
• Box 74: Quick Facts - INO 1001
• Box 75: Quick Facts - CP 4055
• Box 76: Quick Facts - AP 12009
• Box 77: Quick Facts - Ecromeximab
• Box 78: Quick Facts - ILX 651
• Box 79: Quick Facts - Kahalalide F
• Box 80: Quick Facts - ABX MA1
• Box 81: Quick Facts - MJV 101
• Box 82: Quick Facts - Russian Melanoma Vaccine
• Box 83: Quick Facts - N-Acetyl-GM3 ganglioside
• Box 84: Quick Facts - F 50040
• Box 85: KpOmpA Technology